EAM
RCKT icon

Eventide Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Eventide Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-770,691
Closed -$5.14M – 250
2025
Q1 		$5.14M Hold
770,691
– – 0.1% 144
2024
Q4 		$9.69M Hold
770,691
– – 0.18% 132
2024
Q3 		$14.2M Hold
770,691
– – 0.25% 104
2024
Q2 		$16.6M Buy
770,691
+279,959
+57% +$6.43M 0.28% 102
2024
Q1 		$13.2M Hold
490,732
– – 0.21% 109
2023
Q4 		$14.7M Sell
490,732
-407,268
-45% -$8.99M 0.24% 105
2023
Q3 		$18.4M Hold
898,000
– – 0.33% 90
2023
Q2 		$17.8M Hold
898,000
– – 0.3% 90
2023
Q1 		$15.4M Buy
898,000
+427,346
+91% +$8.37M 0.28% 98
2022
Q4 		$9.21M Buy
+470,654
New +$8.67M 0.18% 112
2020
Q4 		– Sell
-1,550,000
Closed -$35.4M – 163
2020
Q3 		$35.4M Hold
1,550,000
– – 0.69% 50
2020
Q2 		$32.4M Buy
1,550,000
+135,000
+10% +$2.43M 0.71% 54
2020
Q1 		$19.7M Hold
1,415,000
– – 0.64% 61
2019
Q4 		$32.2M Hold
1,415,000
– – 0.91% 43
2019
Q3 		$16.5M Buy
1,415,000
+420,686
+42% +$5.22M 0.54% 61
2019
Q2 		$14.9M Buy
994,314
+285,714
+40% +$4.99M 0.45% 70
2019
Q1 		$12.4M Hold
708,600
– – 0.43% 69
2018
Q4 		$10.5M Buy
708,600
+314,015
+80% +$5.21M 0.46% 67
2018
Q3 		$9.71M Hold
394,585
– – 0.36% 77
2018
Q2 		$7.75M Hold
394,585
– – 0.32% 82
2018
Q1 		$7.4M Buy
+394,585
New +$6.43M 0.35% 77

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Eventide Asset Management's RCKT Position: Q2 2025 in Review

Eventide Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 770,691 shares — an estimated $5.14M sold.

Eventide Asset Management first reported a position in RCKT in Q1 2018 and held it in 21 quarters. The position peaked at $35.4M in Q3 2020. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Eventide Asset Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Eventide Asset Management sold 770,691 Rocket Pharmaceuticals shares in Q2 2025, an estimated $5.14M.
  • Eventide Asset Management first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 21 quarters.
  • Eventide Asset Management's Rocket Pharmaceuticals position peaked at $35.4M in Q3 2020.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Eventide Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.